Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anna Vedina

Internal Medicine North Chesterfield, VA Medical Doctor

NPI 1801093281 CMS profile 172700

9460 Amberdale Dr, North Chesterfield, VA 23236

Open in the dashboard

General payments

$1,618

106 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anna Vedina of North Chesterfield, VA is reported in the CMS Open Payments database as having received $1,618 across 106 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $450 26
2024 General $94 5
2021 General $164 11
2020 General $415 29
2019 General $496 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anna Vedina
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Anna Vedina were reported at $450. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Anna Vedina Internal Medicine median Middle half National median
2019 $496 $159 $48–$570 $163
2020 $415 $119 $33–$402 $114
2021 $164 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $94 $154 $47–$537 $164
2025 $450 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $320 19 payments
  2. Novo Nordisk Inc $310 20 payments
  3. Lilly USA, LLC $272 23 payments
  4. Pfizer Inc. $117 7 payments
  5. GlaxoSmithKline, LLC. $112 7 payments
  6. AbbVie, Inc. $89 5 payments
  7. Relypsa, Inc. $59 3 payments
  8. Abbott Laboratories $57 3 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $50 3 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $47 3 payments
  11. Other $186 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,596 104 payments
  2. Education $22 2 payments
Products named General payments · program years 2019–2025
  1. Ozempic $216 14 payments
  2. RYBELSUS $152 9 payments
  3. TRULICITY $135 11 payments
  4. FARXIGA $134 6 payments
  5. TRELEGY ELLIPTA $112 7 payments
  6. SYMBICORT $102 4 payments
  7. JARDIANCE $88 9 payments
  8. BYDUREON $81 2 payments
  9. QULIPTA $76 4 payments
  10. UBRELVY $76 4 payments
  11. Other $1,250 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 153 drugs

Part D claims

10,024

Median for Internal Medicine: 777

Drug cost

$525,508

Median for Internal Medicine: $73,373

Branded share of claims

17.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 59 $70,576
Eliquis Apixaban Brand 72 $64,259
Januvia Sitagliptin Phosphate Brand 70 $59,978
Ozempic Semaglutide Brand 35 $45,094
Jardiance Empagliflozin Brand 28 $39,247
Xarelto Rivaroxaban Brand 34 $37,759
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 24 $24,296
Farxiga Dapagliflozin Propanediol Brand 27 $20,493
Trulicity Dulaglutide Brand 11 $18,489
Xtampza Er Oxycodone Myristate Brand 11 $12,776

The 10 drugs with the highest cost, of 153 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$70,033

Of which drugs: $7,753

Medicare patients

402

Average age 74

Services billed

2,526

281 women, 121 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Diabetes 27%
Ischemic heart disease 21%
Depression 20%
Osteoporosis 17%
Chronic kidney disease 15%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 11 11 $3,213
Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older 90732 Office 20 20 $2,616
Vaccine for influenza for injection into muscle 90653 Office 22 22 $1,800

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RYBELSUS
  • Novo Nordisk Inc $17
$17 — —
Ozempic
  • Novo Nordisk Inc $17
$17 35 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $14
$14 — —
MOUNJARO
  • Lilly USA, LLC $12
$12 59 —
ZEPBOUND
  • Lilly USA, LLC $12
$12 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

106 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record